Drugs / ATUZABRUTINIB
ATUZABRUTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04992546 | Aug 2021 → Dec 2022 | atopic eczema | Principia Biopharma, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATUZABRUTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4114766 ↗ |
| Known as | PRN473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04992546 ↗ |
| Known as | SAR444727 | “Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis” NCT04992546 ↗ |
| Modality | Small molecule | — CHEMBL4114766 ↗ |
| Route | Topical | “Topically Administered PRN473 (SAR444727)” NCT04992546 ↗ |